| Name | Title | Contact Details |
|---|
Gympass is a complete corporate wellbeing platform that ignites every journey to feel good. We`re reinventing wellbeing, making it engaging and accessible. Worldwide companies rely on Gympass` unmatched variety, convenience, and flexibility to support their employees` health and happiness. We partner with best in class wellbeing providers in multiple markets across North America, Latin America, and Europe. With over 50,000 fitness partners, 1,300 on demand classes, 2,000 hours of meditation, 1,000 healthy recipes, weekly 1:1 therapy sessions, and hundreds of personal trainers, Gympass supports every wellbeing journey.
Vantage Oncology is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Manhattan Beach, CA. To find more information about Vantage Oncology, please visit www.vantageoncology.com
Moore Norman Technology Center is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Physician Partners was founded in 2015 to provide a better alternative to hospitals for their clinical outsourcing needs. Since its inception, the company has grown to more than 160 care sites and has become a recognized leader in the provision of exceptional emergency medicine and hospital medicine management services to hospitals and healthcare systems nationwide. APP has earned its 100 percent client retention rate by remaining true to its purpose of exceeding the expectations of its patients, providers and hospital partners.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.